

TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

ETAS ID: TM319429

SUBMISSION TYPE:	NEW ASSIGNMENT		
NATURE OF CONVEYANCE:	SECURITY INTEREST		
CONVEYING PARTY DATA			
Name	Formerly	Execution Date	Entity Type
IPD ANALYTICS, LLC		10/03/2014	LIMITED LIABILITY COMPANY: FLORIDA
RECEIVING PARTY DATA			
Name:	SUNTRUST BANK		
Street Address:	1170 Kane Concourse		
Internal Address:	Suite 300		
City:	Bay Harbor Islands		
State/Country:	FLORIDA		
Postal Code:	33154		
Entity Type:	CORPORATION: GEORGIA		
PROPERTY NUMBERS Total: 1			
Property Type	Number	Word Mark	
Registration Number:	4267157	IPDANALYTICS	
CORRESPONDENCE DATA			
Fax Number:			
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>			
Phone:	7543001500		
Email:	Info@ConceptLaw.com		
Correspondent Name:	Scott D. Smiley		
Address Line 1:	200 South Andrews Avenue		
Address Line 2:	Suite 100		
Address Line 4:	Fort Lauderdale, FLORIDA 33301		
ATTORNEY DOCKET NUMBER:	TS_IPD_SA_10-03-14		
NAME OF SUBMITTER:	Scott D. Smiley		
SIGNATURE:	/Scott D. Smiley/		
DATE SIGNED:	10/08/2014		
Total Attachments: 11			
source=Security Agreement for Trademark Recordation#page3.tif			
source=Security Agreement for Trademark Recordation#page4.tif			
source=Security Agreement for Trademark Recordation#page5.tif			

OP \$40.00 4267157

TRADEMARK

source=Security Agreement for Trademark Recordation#page6.tif
source=Security Agreement for Trademark Recordation#page7.tif
source=Security Agreement for Trademark Recordation#page8.tif
source=Security Agreement for Trademark Recordation#page9.tif
source=Security Agreement for Trademark Recordation#page10.tif
source=Security Agreement for Trademark Recordation#page11.tif
source=Security Agreement for Trademark Recordation#page12.tif
source=Security Agreement for Trademark Recordation#page13.tif

COPYRIGHT AND TRADEMARK SECURITY AGREEMENT

This Copyright and Trademark Security Agreement, dated this 3rd day of October, 2014, is made by **IPD ANALYTICS, LLC**, a Florida limited liability company, with its principal place of business at 1170 Kane Concourse, Suite 300, Bay Harbor Islands, Florida, 33154 (hereinafter called the "**Debtor**"), in favor of **SUNTRUST BANK**, a Georgia banking corporation with offices at 515 East Las Olas Boulevard, Seventh Floor, Fort Lauderdale, Florida, 33301 (hereinafter called the "**Secured Party**") for valuable consideration, receipt of which is acknowledged.

WHEREAS, under the terms of the Security Agreement of even date herewith, the Debtor has granted to the Secured Party, for the benefit of the Secured Party, a security interest in, among other property, certain Copyrights and Trademarks (as defined below) of the Debtor, in order to secure the obligations of Debtor and Intellectual Property Development, Inc. (collectively, the "Borrower") to Secured Party under that certain Commercial Note of even date herewith (the "Note") and has agreed as a condition thereof to execute this Copyright and Trademark Security Agreement for recording with the U.S. Copyright Office and any other appropriate governmental authorities.

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Debtor agrees as follows:

SECTION 1. Grant of Security. The Debtor hereby grants to the Secured Party, a security interest in the Debtor's right, title and interest in and to the following (all of the following items or types of property being herein collectively referred to as the "Copyright and Trademark Collateral"), whether now owned or existing or hereafter acquired or arising:

- (i) Copyright and Trademark registrations described in attached Exhibit A, together with all extensions and renewals;
- (ii) all rights in the foregoing provided by international treaties or conventions, all rights corresponding thereto throughout the world and all other rights of any kind whatsoever of the Debtor accruing thereunder or pertaining thereto;
- (iii) each exclusive Copyright license and Trademark license to which the Debtor is a party, including, without limitation, each Copyright license and Trademark license referred to in attached Exhibit A hereto;
- (iv) any and all claims for damages and injunctive relief for past, present and future infringement, violation, misuse or breach with respect to any of the foregoing, with the right, but not the obligation, to sue for and collect, or otherwise recover, such damages; and
- (v) any and all proceeds of, collateral for, income, royalties and other payments now or hereafter due and payable with respect to, and supporting obligations relating to, any and all of the foregoing.

SECTION 2. Warranties and Covenants of Debtor. Debtor warrants and covenants that:

- (a) The Debtor is the owner of the Copyright and Trademark Collateral free from any adverse lien, security interest or encumbrance and Debtor will defend the Copyright and Trademark Collateral against all claims and demands of all persons at any time claiming the same or any interest therein.
- (b) No Financing Statement covering any of the Copyright and Trademark Collateral or any proceeds thereof is on file in any public office, except in favor of the Secured Party. The Debtor shall

immediately notify the Secured Party in writing of any change in name, address, identity or corporate structure from that shown in this Agreement and shall also upon demand furnish to the Secured Party such further information and shall execute and deliver to the Secured Party such financing statements and other documents in a form satisfactory to the Secured Party and shall do all such acts and things as the Secured Party may at any time or from time to time reasonably request or as may be necessary or appropriate to establish and maintain a perfected security interest in the Copyright and Trademark Collateral as security for the obligations of Borrower to Secured Party under the Note (the "Obligations"), subject to no adverse liens or encumbrances; and the Debtor will pay the cost of filing the same or filing or recording this agreement in all public offices wherever filing or recording is deemed by the Secured Party to be necessary or desirable. A carbon, photographic or other reproduction of this agreement is sufficient as a financing statement.

(c) The Debtor will not sell or offer to sell, assign, pledge, lease or otherwise transfer or encumber the Copyright and Trademark Collateral or any interest therein, without the prior written consent of the Secured Party.

(d) The Debtor will keep the Copyright and Trademark Collateral free from any adverse lien, security interest or encumbrance, shall not waste or destroy the Copyright and Trademark Collateral or any part thereof, and shall not use the Copyright and Trademark Collateral in violation of any statute, ordinance or policy of insurance thereon.

SECTION 3. No Transfer of Debtor's Rights. The Debtor agrees not to sell, license, exchange, assign, or otherwise transfer or dispose of, or grant any rights with respect to, or mortgage or otherwise encumber, any of the Copyright and Trademark Collateral.

SECTION 4. Security for Secured Obligations. The grant of continuing security interest in the Copyright and Trademark Collateral by the Debtor under this Copyright and Trademark Security Agreement secures the payment of all Obligations of the Debtor, now or hereafter existing under or in respect of the Note and the related Loan Documents, whether direct or indirect, absolute or contingent, and whether for principal, reimbursement obligations, interest, premiums, penalties, fees, indemnifications, contract causes of action, costs, expenses or otherwise.

SECTION 5. Recordation. The Debtor authorizes and requests that the Register of Copyrights and Trademarks and any other applicable government office record this Copyright and Trademark Security Agreement.

SECTION 6. Execution in Counterparts. This Copyright and Trademark Security Agreement may be executed in any number of counterparts, each of which when so executed shall be deemed to be an original and all of which taken together shall constitute one and the same agreement.

SECTION 7. Grants, Rights and Remedies. This Copyright and Trademark Security Agreement has been executed and delivered by the Debtor for the purpose of recording the grant of security interest herein with the U.S. Copyright Office. The security interest granted hereby has been granted to the Secured Party in connection with this Copyright and Trademark Security Agreement and is expressly subject to the terms and conditions thereof and does not create any additional rights or obligations for any party hereto. This Copyright and Trademark Security Agreement (and all rights and remedies of the Secured Party thereunder) shall remain in full force and effect in accordance with its terms.

SECTION 8. Governing Law. This Copyright and Trademark Security Agreement shall be governed by, and construed in accordance with, the laws of the State of Florida.

SECTION 9. General. No waiver by the Secured Party of any default shall operate as a waiver of

any other default or of the same default on a future occasion. All rights of the Secured Party hereunder shall inure to the benefit of its successors and assigns; and all obligations of the Debtor shall bind its successors or assigns. This agreement shall become effective when it is signed by the Debtor.

All rights of the Secured Party in, to, and under this agreement and in and to the Copyright and Trademark Collateral shall pass to and may be exercised by any assignee thereof. The Debtor agrees that if the Secured Party gives notice to the Debtor of an assignment of said rights, upon such notice, the liability of the Debtor to the assignee shall be immediate and absolute.

If any provision of this agreement shall be prohibited by or invalid under applicable law, such provision shall be ineffective to the extent of such prohibition or invalidity, without invalidating the remainder of such provision or the remaining provisions of this agreement.

Secured Party:

SunTrust Bank

By: 

Name: John W. Winn

Title: First Vice President

Debtor:

IPD Analytics, LLC

By: 

Name: Howard B. Krass

Title: General Manager

Security Agreement

EXHIBIT A

No.	Full Title	Copyright Reg. Number	Reg. Date
1.	Haemonetics v. Fenwal: Appeals Court Likely Will Overturn Trial Decision In Favor of Haemonetics.	TX0007371649	2011-02-25
2.	Gen-Probe (GPRO) V. Becton Dickinson (BDX): An Early Look at the BD Viper and BD ProbeTec Lawsuit.	TX0007371652	2011-02-25
3.	Palomar v. Syneron: Palomar Appears To Have Early Advantage In Lawsuit.	TX0007379922	2011-02-25
4.	Cook Medical v. Endologix (ELGX): Endologix Unlikely To Face Injunction.	TX0007379893	2011-02-25
5.	Nokia v. Apple: ITC Patent Lawsuits Threaten Each Company's Key Products.	TX0007371746	2011-02-25
6.	Rambus: Rambus At Risk Of Adverse Outcome In Spoliation Appeals; Appeals Decisions May Jeopardize Other Rambus Lawsuits.	TX0007371742	2011-02-25
7.	Survey Of Apple's Patent Infringement Lawsuits.	TX0007371741	2011-02-25
8.	Apple (AAPL) v. HTC: ITC Lawsuits Threaten Each Company's Key Products.	TX0007371730	2011-02-25
9.	Akamai V. Limelight: Appeal Appears To Threaten Limelight Trial Victory.	TX0007371726	2011-02-25
10.	I2 v. Oracle: I2 Holds Overall Advantage In Patent Duel With Oracle.	TX0007371724	2011-02-25
11.	Oracle v. Google: Oracle Holds Early Advantage Against Google.	TX0007371722	2011-02-25
12.	Rambus v. Micron & Hynix : Appeals Court Likely Will Rule Against Rambus On Spoliation But Likely Will Vacate And Remand Unenforceability Sanction.	TX0007371723	2011-02-25
13.	KCI v. SNN (NPWT Systems): Jury Trial Begins Tomorrow.	TX0007379603	2011-02-25
14.	Illumina v. Life: Appeals Court Likely Will Affirm January 2009 Jury Verdict in Favor of Life.	TX0007379606	2011-02-25
15.	Life v. Illumina: An Early Look At The Recent Life v. Illumina Lawsuit.	TX0007379607	2011-02-25
16.	Medtronic (MDT) v. NuVasive (NUVA); First Phase Overview, Medtronic Appears To Have Slight Advantage.	TX0007379608	2011-02-25
17.	Philips v. Zoll Medical: An Early Look.	TX0007379609	2011-02-25
18.	St. Jude V. Volcano (STJ, VOLC): A Survey Of The Parties' Lawsuits.	TX0007379611	2011-02-25
19.	Becton, Dickinson v. Insulet (BDX, PODD) Update: An Early Look.	TX0007379612	2011-02-25

20.	Life and Cornell University v. Illumina (LIFE ILMN): An Early Look At Another Life v. Illumina Lawsuit.	TX000737961 3	2011-02-25
21.	AMP v. Myriad (MYGN): Lawsuit Unlikely to Significantly Impact Myriad's Blocking Position.	TX000737165 1	2011-02-25
22.	AMP v. Myriad Genetics (MYGN): Myriad Appears To Hold Advantage On Overturning All Or At Least Some Of District Court's Invalidity Decision.	TX000737961 4	2011-02-25
23.	Amrix (Ceph): Patent Office Soon Will Issue New Patent With Improved Protection For Amrix.	TX000738795 5	2011-04-13
24.	Angiomax Update (MDCO): Solicitor General Elects Not to Appeal Patent Term Extension; Angiomax Unlikely to Face Generic Competition Until June 2015.	TX000738792 5	2011-04-13
25.	Viagra (PFE): Pfizer Has Advantage Defending Viagra From Generic Competition Until 2019.	TX000738798 6	2011-04-13
26.	Temodar: Although A Close Call, Upcoming Appeals Court Decision Most Likely Will Permit Teva To Launch Generic Temodar.	TX000738792 7	2011-04-13
27.	Pomalidomide: An Early Look At The Pomalidomide Patent Situation.	TX000738791 7	2011-04-13
28.	Enablex (WCRX TEVA WPI): An Early Look At The Generic Enablex Patent Litigation.	TX000738792 2	2011-04-13
29.	Neupogen/Neuroval: An Early Look At The Neuroval Litigation.	TX000738791 9	2011-04-13
30.	Strattera: Appeals Court Appears Inclined To Rule For Lilly And Prevent Generic Competition Until May 2017.	TX000738795 2	2011-04-13
31.	Laquinimod (TEVA): An Early Look At The Laquinimod Patent Situation.	TX000738790 7	2011-04-13
32.	Adderall XR Report (SHPGY, TEVA, IPXL, WPI, Actavis, Sandoz): Adderall XR May Not Face Additional Generic Competition Until 2012 or Later.	TX000738797 6	2011-04-13
33.	Truvada & Atripla (GILD TEVA): Gilead Has Advantage Defending Drugs From Generic Competition Until 2021.	TX000738792 0	2011-04-13
34.	Sanctura XR (AGN v WPI, NVS, Paddock): An Early Look.	TX000738804 7	2011-04-13
35.	Xyrem: An Early Look At The Xyrem Patent Situation.	TX000738803 4	2011-04-13
36.	Lovaza (Pronova, GSK v. TEVA, Apotex, PRX): Pronova Appears To Have Advantage On Excluding Competition Until At Least 2013.	TX000738800 4	2011-04-13
37.	Cubicin: Cubist Appears To Have Advantage Heading Into Markman Hearing.	TX000738804 9	2011-04-13
38.	Lumigan: Allergan Appears To Have Advantage In Patent Lawsuit.	TX000738807 0	2011-04-13
39.	Crestor (AZN): Parties Await Trial Decision on 2016 Patent; Method-of-Use Patents May Provide Additional Protection against Generic Competition.	TX000738806 7	2011-04-13

40.	Allegra-D 24 Hour: An In-Depth Look At The Allegra-D 24 Hour Preliminary Injunction Motion.	TX0007388058	2011-04-13
41.	Mucinex: Appeals Court Appears Inclined To Vacate Perrigo's Summary Judgment Victory and Return Case to District Court.	TX0007388044	2011-04-13
42.	Cubicin (CBST V. TEVA): Cubist Appears to Have Advantage in Defending 2019 Dosing Patents Against Teva's New Allegations of Inequitable Conduct.	TX0007388039	2011-04-13
43.	Strattera: Generics Appear To Have Advantage In Proving Lilly's Strattera Patent Invalid.	TX0007388042	2011-04-13
44.	Evista (LLY TEVA): Appeals Court Likely Will Affirm Decision Excluding Generic Competition Until 2014.	TX0007387892	2011-04-13
45.	Embeda (KG): Early Look at Litigation; Summary Judgment Hearing Tomorrow.	TX0007387947	2011-04-13
46.	Temodar: Teva Has Advantage Entering August 4 Appeal Hearing.	TX0007387933	2011-04-13
47.	Patanol (ACL): Although a Close Call, Alcon Appears to Have the Advantage in Excluding Generic Competition Until 2015.	TX0007387944	2011-04-13
48.	Abilify: Otsuka and Bristol-Myers Have Advantage Heading Into Trial.	TX0007387913	2011-04-13
49.	Xyzal (PRGO): An Early Look at the UCB v. Synthon Lawsuit.	TX0007387911	2011-04-13
50.	Fentora (CEPH v. WPI): Trial Decision Likely Will Favor Watson, but Citizen Petitions May Delay Approval.	TX0007387905	2011-04-13
51.	Gemzar (LLY v. TEVA): District Court Most Likely Will Uphold 2010 Patent But Strike Down 2013 Patent.	TX0007388072	2011-04-13
52.	Taxotere (SNY, HSP, APOTEX): Although A Close Call, District Court Likely Will Issue Decision In Favor of Sanofi.	TX0007388064	2011-04-13
53.	Copaxone Report (TEVA, MNTA, NVS): Teva Appears to Have Advantage Heading Into Tomorrow's Markman Hearing.	TX0007388055	2011-04-13
54.	INCB18424 (INCY): Composition-of-Matter Patent Appears to Protect INCB18424 Through At Least December 2027.	TX0007388027	2011-04-13
55.	Avonex (BIIB): An In-Depth Look at the 2026 Avonex Patent.	TX0007388008	2011-04-13
56.	Mucinex: An In-Depth Look at the Upcoming Mucinex Trial.	TX0007388012	2011-04-13
57.	Zetia: Merck Appears To Have Advantage Despite Possible Flaws in Patent.	TX0007388014	2011-04-13
58.	Combivir: Teva May Have Opportunity To Launch At Risk in May 2010.	TX0007388018	2011-04-13
59.	Treximet: An In-Depth Look at the Treximet Patent Situation.	TX0007388021	2011-04-13
60.	Pirfenidone: An Early Look at the Pirfenidone Patent Situation.	TX0007388061	2011-04-13

61.	Abilify: Bristol-Myers Squibb Appears To Have Advantage in Patent Infringement Litigation.	TX0007388066	2011-04-13
62.	Silenor: Patent Likely To Prevent Generic Competition Until 2020.	TX0007388031	2011-04-13
63.	Zemplar: Generic Competition Possible In October 2012.	TX0007388035	2011-04-13
64.	Viibryd/Vilazodone Report (CLDA): An Initial Look at the Vilazodone Patent Situation.	TX0007387972	2011-04-13
65.	Allegra, Allegra-D 12 Hour, and Allegra-D 24 Hour: An Overview of the Generic Landscape.	TX0007387941	2011-04-13
66.	Nasonex (MRK, Apotex): An Early Look At The Merck v. Apotex Lawsuit.	TX0007387937	2011-04-13
67.	Precedex (HSP): Hospira Has Advantage On 2013 Patent, But Too Early To Assess 2019 Patent.	TX0007387980	2011-04-13
68.	Lyrica (PFE): Pfizer Composition-Of-Matter Patent Likely Will Prevent Generic Competition Until December 2018.	TX0007387982	2011-04-13
69.	Cubicin (CBST v. TEVA): Heading Into Trial, Cubist Appears To Have Advantage.	TX0007387991	2011-04-13
70.	Generic Landscape Analysis: Erectile Dysfunction Drugs.	TX0007387998	2011-04-13
71.	Vimovo (AZN, POZN, RDY): An Initial Look At The Vimovo Patent Situation.	TX0007387912	2011-04-13
72.	C.R. Bard (BCR) v. W.L. Gore: Appeals Court Likely Will Affirm Bard's \$520M Trial Victory.	TX0007387931	2011-04-13
73.	Zoll Lifevest Patents Appear Likely To Exclude Competition Only Until May 2016.	TX0007387928	2011-04-13
74.	Align Technology (ALGN) v. ClearCorrect: Align Has Early Advantage In Patent Infringement Lawsuit.	TX0007387934	2011-04-13
75.	VEGF Trap-Eye (REGN v. Roche): An Early Look At The VEGF Trap-Eye Litigation.	TX0007387908	2011-04-13
76.	Lumigan (AGN, TEVA, Sandoz): Allergan Appears To Have Advantage In Patent Lawsuit Heading Into Trial.	TX0007387995	2011-04-13
77.	Lidoderm (ENDP WPI): An Early Look At The Endo v. Watson Lawsuit.	TX0007392913	2011-05-02
78.	AMR101 (Amarin): An Initial Look at the AMR101 Patent Situation.	TX0007392916	2011-05-02
79.	Lovaza (Pronova v. Teva, Par): Although a Close Call, Lovaza 2013 and 2017 Patents Likely Invalid.	TX0007426007	2011-06-02
80.	Zegerid (SNTS v. PRX): Appeals Court Likely Will Remand Lawsuit Back To District Court For Reconsideration.	TX0007419181	2011-06-02
81.	Neurontin (PFE v. TEVA): Pfizer May Have Difficulty In Gabapentin Patent Infringement Trial.	TX0007423776	2011-06-02
82.	AMP v. Myriad Genetics (MYGN): Appeals Court Appears Inclined To Overturn District Court Decision.	TX0007423775	2011-06-02
83.	Volterra v. Infineon: Jury Trial on Patent Validity Begins Today (Monday, May 9)	TX0007424317	2011-06-02
84.	Lidoderm (ENDP v WPI): Endo Appears To Have Advantage Heading Into Markman Hearing.	TX0007416029	2011-07-06

85.	Viagra (PFE v. TEVA): Heading Into Trial, Pfizer Appears To Have Advantage.	TX0007416034	2011-07-06
86.	Generic and Biosimilar Landscape Analysis: Multiple Sclerosis Monotherapies.	TX0007416036	2011-07-06
87.	C.R. Bard (BCR) v. W.L. Gore: Appeal Appears to Threaten Bard's Trial Victory.	TX0007416038	2011-07-06
88.	Combigan (AGN): Allergan Appears To Have Advantage In Upcoming Trial.	TX0007427942	2011-08-01
89.	Travatan and Travatan Z (NVS, PRX, TEVA): An Initial Look.	TX0007427932	2011-08-01
90.	NuVasive v. Globus: An Early Look At The NuVasive v. Globus Lawsuit.	TX0007427934	2011-08-01
91.	Illumina v. Complete Genomics (ILMN GNOM): An Early Look At The Lawsuit.	TX0007427940	2011-08-01
92.	Generic Landscape Analysis: Angiotensin Receptor Blockers.	TX0007443242	2011-09-01
93.	Sequenom/Lo (SQNM) And Verinata/Quake: The Patent Landscape For Prenatal Down Syndrome Diagnosis.	TX0007443270	2011-09-01
94.	Life v. Illumina (LIFE ILMN): Life Appears To Have The Overall Advantage, But Likely It Must Go To Trial To Prevail.	TX0007443257	2011-09-01
95.	W.L. Gore v. Medtronic (MDT): Lawsuit Does Not Threaten Medtronic's Talent Stent Graft Products.	TX0007443251	2011-09-01
96.	Medtronic v. NuVasive (MDT NUVA): Trial Set To Begin August 30; Mixed Decision Appears Likely.	TX0007443267	2011-09-01
97.	EpiPen (MYL, PFE v. TEVA, AIS): King Appears To Have The Advantage Heading Into Markman Hearing.	TX0007456411	2011-10-03
98.	Competitive Landscape Analysis: Rheumatoid Arthritis Therapies.	TX0007464627	2011-11-01
99.	Nuvigil (TEVA v. MYL): An Initial Look At The Litigation Over Proposed Generic Versions Of Nuvigil.	TX0007464630	2011-11-01
100.	Angiomax (MDCO): An Update On The Patent Litigation Over Proposed Generic Angiomax.	TX0007464634	2011-11-01
101.	Travatan and Travatan Z (NVS V PAR, TEVA): Trial Begins This Week.	TX0007472485	2011-12-02
102.	Lialda (Shire v. Zydus): An Initial Look At The Litigation Over A Proposed Generic Version Of Lialda.	TX0007472483	2011-12-02
103.	AndroGel (ABT, TEVA, BPAX, WPI, PRX): Teva Has Advantage Heading Into Trial, May Launch "At Risk" In 3Q 2012.	TX0007472467	2011-12-02
104.	Edwards Lifesciences v. Medtronic (EW v. MDT): Transcatheter Heart Valve Appeal and Early Stage Litigation Overview.	TX0007472465	2011-12-02
105.	Prometheus v. Mayo: Supreme Court To Consider Patentability Of Certain Medical Technology Methods.	TX0007482309	2012-01-03
106.	LadaTech v. Illumina (ILMN): An Initial Look At The Patent Infringement Lawsuit.	TX0007482304	2012-01-03
107.	Competitive Landscape Analysis: Diabetes Therapies.	TX0007482299	2012-01-03

108.	Intuniv (Shire): Intuniv Faces Threat of Generic Competition in Q4 2012.	TX0007482306	2012-01-03
109.	Enbrel (AMGN, PFE): An Analysis of the 2028 Enbrel Patent.	TX0007482294	2012-01-03
110.	Remodulin (UTHR v. NVS): Remodulin Faces Threat Of Generic Competition In Q4 2014.	TX0007544085	2012-05-16
111.	Testim (AUXL, WPI): An Early Look At The Coming Auxilium v. Watson Lawsuit.	TX0007544030	2012-05-16
112.	Medtronic v. NuVasive (MDT NUVA): Hearing On Post-Trial Motions And Permanent Injunction Set For January 26.	TX0007544177	2012-05-16
113.	Azilect (TEVA): Teva Appears To Have Advantage In Litigation Over Proposed Generic Versions Of Azilect.	TX0007544163	2012-05-16
114.	Revlimid (CELG): An Analysis Of The Polymorph Patent Family.	TX0007544161	2012-05-16
115.	Competitive Landscape Analysis: Lung Cancer Therapies.	TX0007544113	2012-05-16
116.	Exelon Patch (NVS, WPI): Novartis Faces Threat Of Generic Competition In 2014.	TX0007544107	2012-05-16
117.	Qnexa (VVUS): An Overview Of The Qnexa Patent Situation.	TX0007544100	2012-05-16
118.	Vytorin and Zetia (MRK): Judge Appears Concerned About Validity And Enforceability of Merck's Patent.	TX0007544098	2012-05-16
119.	Xyrem (JAZZ v. Roxane): An Introduction To The April 26 Markman Hearing And A Lawsuit Update.	TX0007544095	2012-05-16
120.	Dexilant (Takeda v. Par): Takeda Appears To Have Advantage On 2020 Patents Following Markman Ruling.	TX0007544090	2012-05-16
121.	Align (ALGN) v. ClearCorrect: ITC Lawsuits Threaten ClearCorrect's Products.	TX0007546902	2012-06-01
122.	Impact Of Mayo v. Prometheus On Method-Of-Use Patents In The Pharmaceutical Sector.	TX0007559171	2012-07-02
123.	Zyclara (MRX): Patent Office Set To Issue Two New Patents; Litigation Likely To Follow Quickly.	TX0007577417	2012-08-01
124.	Competitive Landscape Analysis: ADHD Therapies.	TX0007577193	2012-08-01
125.	Pulmicort Respules (AZN v. WPI, Apotex, NVS): An Overview Of The Litigation.	TX0007595629	2012-09-06
126.	Nuedexta (AVNR): An Initial Look.	TX0007595625	2012-09-06
127.	Bystolic (FRX): Bystolic May Face Generic Competition By 2015 Or Sooner.	TX0007595633	2012-09-06
128.	Velcade (Millennium v. Sandoz): Velcade Unlikely To Face Generic Competition Before 2022.	TX0007595631	2012-09-06
129.	Competitive Landscape Analysis: Obesity Therapies.	TX0007595635	2012-09-06
130.	St. Jude Medical (STJ) v. W.L. Gore: An Initial Look At The Helex Septal Occluder Lawsuit.	TX0007595638	2012-09-06
131.	St. Jude Medical (STJ) v. W.L. Gore: An Initial Look At The Helex Septal Occluder Lawsuit.	TX0007606275	2012-10-03

132.	Gralise (DEPO): An Early Look At The Patent Litigation.	TX0007606263	2012-10-03
133.	Overview Of Potential Generic Competition To Controlled-Release Mesalamine Products.	TX0007622311	2012-11-08
134.	Life (LIFE) v. Illumina (ILMN): An Overview Of The Patent Lawsuits Currently Pending Between Life And Illumina.	TX0007622308	2012-11-08
135.	Ofirmev (Cadence): Cadence Appears To Have Advantage On Preventing Generic Competition Until 2018.	TX0007622305	2012-11-08
136.	Gleevec (NVS): Understanding The Timing For Potential Generic Competition.	TX0007622299	2012-11-08
137.	Pulmicort Respules (AZN v. WPI, Apotex, NVS): Heading Into Trial, AstraZeneca Appears To Have Advantage.	TX0007622297	2012-11-08
138.	Zerenex Update (KERX): An Early Look At The Zerenex Patent Portfolio.	TX0007672859	2013-02-05
139.	Align (ALGN) v. ClearCorrect: Approaching Trials Threaten ClearCorrect's Products.	TX0007672964	2013-02-05
140.	Myriad (MYGN): Supreme Court To Consider Validity Of Myriad Patents Covering Isolated DNA.	TX0007720751	2013-04-05
141.	Lialda (SHPG v. ACT): A Preview Of The Coming Trial.	TX0007720755	2013-04-05
142.	Cubicin (CBST v. HSP): Cubist Appears To Have Advantage Heading Into Markman Hearing.	TX0007720758	2013-04-05
143.	AndroGel (ABBV): Supreme Court To Consider Whether Reverse-Payment Agreements Violate Anti-Trust Laws.	TX0007720753	2013-04-05
144.	Enzo (ENZ): An Early Look At Enzo's Recent Patent Lawsuits.	TX0007777035	2013-08-02
145.	Juxtapid (AEGR): Dosing Patent Likely To Protect Juxtapid From Generic Competition Until 2027.	TX0007777006	2013-08-02
146.	Zytiga (JNJ, BTG): An Overview Of The Zytiga Patent Situation.	TX0007776998	2013-08-02
147.	Xifaxan (SLXP): An Overview Of Salix's Patent Portfolio For Xifaxan 550 mg And 200 mg.	TX0007777003	2013-08-02
148.	Drisapersen (Prosensa) And Eteplirsen (Sarepta): An Overview Of The Patent Situation.	TX0007777010	2013-08-02
149.	Amitiza (SCMP): An Early Look At The Patent Litigation.	TX0007777032	2013-08-02
150.	Effient (LLY): An Overview Of Eli Lilly's Patent Portfolio For Effient.	TX0007824332	2013-11-25
151.	Suboxone Film (Reckitt Benckiser): An Early Look At The Patent Litigation.	TX0007824326	2013-11-25
152.	Gilenya (NVS): An Overview Of Novartis's Patent Portfolio.	TX0007824331	2013-11-25
153.	Sequenom, Verinata, Ariosa, & Natera: An Overview Of The Patent Landscape And Upcoming Markman Hearings.	TX0007824323	2013-11-25
154.	Ampyra (ACOR): An Overview Of Acorda's Patent Protection For Ampyra.	TX0007824324	2013-11-25
155.	Competitive Landscape Analysis: PCSK9 Antibodies.	TX0007824329	2013-11-25
156.	Angiomax (MDCO): A Preview Of The Coming Trial Against Hospira.	TX0007824321	2013-11-25
157.	OxyContin (Purdue): A Preview Of The Coming Trial.	TX0007824325	2013-11-25
158.	Truvada & Atripla (GILD v. TEVA): Heading Into Trial, Gilead Appears To Have Advantage.	TX0007824328	2013-11-25

159.	Prezista (JNJ): Prezista May Face Generic Competition in 2019.	TX0007824322	2013-11-25
160.	Hetlioz (VNDA): An Overview Of Vanda's Patent Portfolio.	TX0007846279	2013-12-23
161.	Velcade (Millennium): Velcade Unlikely To Face Generic Competition Before 2022.	TX0007846276	2014-01-07
162.	Edwards & Medtronic (EW, MDT): Tavi Patent Landscape.	TX0007846167	2014-01-07
163.	InterDigital (IDCC) v. Nokia, Huawei, and ZTE: InterDigital Likely to Suffer Strategic Loss at ITC.	TX0007846290	2014-01-07
No.	Mark	Trademark Reg. Number	Reg. Date
1.	IPDANALYTICS (+ Design)	4267157	01/01/2013